Risk Factor Associated with Recurrence after OM-89 (Uro-Vaxom®) Treatment for Female Recurrent Cystitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study evaluated the risk factors associated with recurrence OM-89 (Uro-Vaxom®) treatment for female recurrent cystitis.Materials and Methods: The medical records of patients who received OM-89 for at least six months were reviewed retrospectively. Patients were excluded from the analysis if they had an abnormal lower urinary tract anatomy, residual urine volume ≥200 ml, a history of genitourinary tuberculosis, urological cancer or pelvic radiation, indwelling urinary catheter, or had genitourinary surgery within the previous six months. Patients were categorized into two groups: (1) no recurrence and (2) recurrent cystitis after OM-89. The risk factors in the two groups were compared. The recurrent cystitis was defined as two more infections in six months or three or more in one year.Results: A total of 52 female were included. Group 1 had 35 (67.3%) patients and group 2 had 17 (32.7%) patients. Before and after the OM-89, the mean cystitis episodes for six months of groups 1 and 2 were 4.19±4.60 (range, 2-24) and 1.17±1.79 (range, 0-6), respectively, which were decreased significantly (p＜0.001). For recurrence after the OM-89, the only risk factor was uncontrolled diabetes (fasting plasma glucose level ＞120 mg/dl±casual plasma glucose ＞180 mg/dl) (p=0.002). No significant differences in the age, menopause, daily water intake, hormone replacement therapy or history of extended-spectrum beta-lacta-mase-producing Escherichia coli were observed between the two groups.Conclusions: OM-89 was effective in the management of recurrent cystitis in female. On the other hand, uncontrolled diabetes was a risk factor for treatment failure of OM-89.
Abstract
Purpose: This study evaluated the risk factors associated with recurrence OM-89 (Uro-Vaxom®) treatment for female recurrent cystitis.Materials and Methods: The medical records of patients who received OM-89 for at least six months were reviewed retrospectively. Patients were excluded from the analysis if they had an abnormal lower urinary tract anatomy, residual urine volume ≥200 ml, a history of genitourinary tuberculosis, urological cancer or pelvic radiation, indwelling urinary catheter, or had genitourinary surgery within the previous six months. Patients were categorized into two groups: (1) no recurrence and (2) recurrent cystitis after OM-89. The risk factors in the two groups were compared. The recurrent cystitis was defined as two more infections in six months or three or more in one year.Results: A total of 52 female were included. Group 1 had 35 (67.3%) patients and group 2 had 17 (32.7%) patients. Before and after the OM-89, the mean cystitis episodes for six months of groups 1 and 2 were 4.19±4.60 (range, 2-24) and 1.17±1.79 (range, 0-6), respectively, which were decreased significantly (p＜0.001). For recurrence after the OM-89, the only risk factor was uncontrolled diabetes (fasting plasma glucose level ＞120 mg/dl±casual plasma glucose ＞180 mg/dl) (p=0.002). No significant differences in the age, menopause, daily water intake, hormone replacement therapy or history of extended-spectrum beta-lacta-mase-producing Escherichia coli were observed between the two groups.Conclusions: OM-89 was effective in the management of recurrent cystitis in female. On the other hand, uncontrolled diabetes was a risk factor for treatment failure of OM-89.
참고문헌 (12)
- Foxman B., "Epidemiology of urinary tract infections: incidence, morbidity, and economic costs", Am J Med, 113(Suppl 1A), pp.5S~13S (2002)
- Foxman B, "Recurring urinary tract infection : incidence and risk factors", Am J Public Health, 80, pp.331~333 (1990)
- Scholes D, "Risk factors for recurrent urinary tract infection in young women", J Infect Dis, 182, pp.1177~1182 (2000)
- Albert X, "Antibiotics for preventing recurrent urinary tract infection in non-pregnant women", Cochrane Database Syst Rev, pp.CD001209~ (2004)
- Beerepoot MA, "Nonantibiotic prophylaxis for recurrent urinary tract infections : a systematic review and meta-analysis of randomized controlled trials", J Urol, 190, pp.1981~1989 (2013)
- Naber KG, "Immunoactive prophylaxis of recurrent urinary tract infections : a metaanalysis", Int J Antimicrob Agents, 33, pp.111~119 (2009)
- Stamm WE, "Natural history of recurrent urinary tract infections in women", Rev Infect Dis, 13, pp.77~84 (1991)
- Schmidhammer S, "An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells", Urology, 60, pp.521~526 (2002)
- 이승주, "재발성 단순방광염 환자에서 유로박솜의 치료 효과 및 안전성: 다기관 공개 임상연구", Investigative and Clinical Urology, 48(4), pp.428~432 (2007), 대한비뇨의학회
- Geerlings SE, "Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli : studies with urine from diabetic and non-diabetic individuals", J Med Microbiol, 48, pp.535~539 (1999)
- Geerlings SE, "Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells : more in diabetic women than in control subjects", Diabetes Care, 25, pp.1405~1409 (2002)
- Delamaire M, "Impaired leucocyte functions in diabetic patients", Diabet Med, 14, pp.29~34 (1997)